Daclizumab 150mg/1ml solution for injection pre-filled disposable devices
Humanized IgG1 Mab that binds to the human interleukin-2 receptor (anti-Tac or anti-CD25).
Official documents, adverse reaction reporting, and safety monitoring
Report a side effect
Submit a Yellow Card report to the MHRA
Safety monitoring data
Yellow Card reports
The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.
View Drug Analysis Profile
Suspected adverse reactions reported for Daclizumab
Browse all iDAP reports
Interactive Drug Analysis Profiles for all medicines
Report a side effect
Submit a Yellow Card report to the MHRA
Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.
EudraVigilance
The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.
View EudraVigilance report
Suspected adverse reactions reported for Daclizumab
About EudraVigilance
Learn about EU pharmacovigilance and safety monitoring
EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.
1 branded products available
WHO defined daily dose (DDD)
5 mg
Not a recommended dose. The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. It is a statistical measure used for research and comparison purposes only.
Source: WHO Collaborating Centre for Drug Statistics Methodology, distributed via NHS dm+d BNF mapping files. Contains public sector information licensed under the Open Government Licence v3.0.
Therapeutically similar medicines
Similarity based on WHO Anatomical Therapeutic Chemical (ATC) classification and NHS BNF section grouping. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.
NHS prescribing volume and spending trends
Clinical guidelines and formulary information
British National Formulary
Daclizumab
Source: British National Formulary, NICE. Joint Formulary Committee. Contains public sector information licensed under the Open Government Licence v3.0.
NICE clinical guidance(3)
Immunosuppressive therapy for kidney transplant in children and young people (TA482)
Beta interferons and glatiramer acetate for treating multiple sclerosis (TA527)
Ocrelizumab for treating relapsing–remitting multiple sclerosis (TA533)
Source: National Institute for Health and Care Excellence (NICE). Contains public sector information licensed under the Open Government Licence v3.0.
Check stock at pharmacies and supply information
Pharmacy stock checkers
Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.
Supply & product information
Official product databases and supply status monitoring
Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. emc (electronic medicines compendium) is operated by Datapharm Ltd. Shortage information sourced from NHS Specialist Pharmacy Service (SPS), sps.nhs.uk.
Codes for healthcare professionals and prescribing systems
These codes are used by healthcare IT systems and prescribers to identify this medicine.
NHS UK identifiers
Browse tools
SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. BNF codes from NHS Business Services Authority (NHSBSA). ATC codes from the WHO Collaborating Centre for Drug Statistics Methodology (whocc.no).
Active and completed clinical studies from ClinicalTrials.gov
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.
Pharmacology and chemical data from DrugBank
Key facts
Drug status
Approved
Major interactions
None known
Half-life
11-38 days
Mechanism
Zenepax binds with high-affinity to the Tac subunit of the high-affinity IL-2 re…
Food interactions
None known
Human targets
12 targets
Data: DrugBank · CC BY-NC 4.0
Pharmacokinetics at a glance
Half-life
11-38 days
Metabolism
Pharmacokinetic data: DrugBank · CC BY-NC 4.0
On 22 April 2008, Roche Registration Limited chose to voluntarily withdraw the marketing authorization for their product Zenapax (daclizumab), as indicated for the prophylaxis of acute organ rejection in de novo allogeneic renal transplantation and used concomitantly with an immunosuppressive regimen like cyclosporine and corticosteroids in patients who are not hight immunized, for commercial reasons and confirmed that this decision was not related to any safety concerns associated with the use of Zenapax (daclizumab) [L1744]. Regardless of the withdrawal of Zenapax, Biogen and Abbvie's Zinbryta (daclizumab), as indicated for the treatment of adult patients with relapsing forms of multiple sclerosis, was approved for use by the FDA in 2016 [L1746].
Despite being approved for use, Zinbryta (daclizumab)'s complex pre-existing safety profile consisting of its restricted availability through a Risk Evaluation and Mitigation Strategy program [L1738] and its black box warning for possible hepatic injury, autoimmune hepatitis, and other immune mediated disorders [L1738] meant its therapeutic usage, adverse effects, and prescribing information was subject to continuous monitoring and updating.
Although Zinbryta (daclizumab) was available for patients as needed until 30 April 2018, Biogen and Abbvie announced a voluntary withdrawal of their product Zinbryta (daclizumab) from the global market on 2 March 2018 [L1738]. This withdrawal was concurrent to the European Medicines Agency announcement of a recall owing to 12 worldwide reports of serious inflammatory brain disorders associated with the use of Zinbryta (daclizumab) [L1738].
Known interactions with other medications. Always consult a healthcare professional.
Showing 50 of 681 interactions
How the body processes this drug — absorption, distribution, metabolism, and elimination
Proteins and enzymes this drug interacts with in the body
Contrary to III-A, is not capable to mediate antibody-dependent cytotoxicity and phagocytosis. May serve as a trap for immune complexes in the peripheral circulation which does not activate neutrophils
PMID:17996945 PMID:19473974 PMID:29449492
C1R catalyzes the first enzymatic step in the classical complement pathway: it is activated by the C1Q subcomplex of the C1 complex, which associates with IgG or IgM immunoglobulins complexed with antigens to form antigen-antibody complexes on the surface of pathogens .
PMID:29449492 PMID:34155115
Immunoglobulin-binding promotes the autocatalytic cleavage and activation of C1R .
PMID:11445589 PMID:11673533 PMID:17996945 PMID:20178990 PMID:6254570 PMID:6271784
Activated C1R then cleaves and activates C1S, the second protease of the classical complement pathway .
PMID:11445589 PMID:11673533 PMID:6271784
It is unclear if C1R activates C1S within single, strained C1 complexes or between neighboring C1 complexes on surfaces PMID:28104818 PMID:29311313 PMID:29449492
PMID:12847249 PMID:19006321 PMID:24626930 PMID:29449492 PMID:3258649 PMID:34155115 PMID:6249812 PMID:6776418
The classical complement pathway is initiated by the C1Q subcomplex of the C1 complex, which specifically binds IgG or IgM immunoglobulins complexed with antigens, forming antigen-antibody complexes on the surface of pathogens: C1QA, together with C1QB and C1QC, specifically recognizes and binds the Fc regions of IgG or IgM via its C1q domain .
PMID:12847249 PMID:19006321 PMID:24626930 PMID:29449492 PMID:3258649 PMID:6776418
Immunoglobulin-binding activates the proenzyme C1R, which cleaves C1S, initiating the proteolytic cascade of the complement system .
PMID:29449492
The C1Q subcomplex is activated by a hexamer of IgG complexed with antigens, while it is activated by a pentameric IgM .
PMID:19706439 PMID:24626930 PMID:29449492
The C1Q subcomplex also recognizes and binds phosphatidylserine exposed on the surface of cells undergoing programmed cell death, possibly promoting activation of the complement system PMID:18250442
ATC L04AC01
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Show
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Linked compound data from DrugBank Open Data (CC BY-NC 4.0)
Daclizumab
Additional database identifiers
Drugs Product Database (DPD)
11957
Drugs Product Database (DPD)
22834
HUGO Gene Nomenclature Committee (HGNC)
HGNC:6008
GenAtlas
IL2RA
GeneCards
IL2RA
GenBank Gene Database
X01057
GenBank Protein Database
33813
Guide to Pharmacology
1695
UniProt Accession
IL2RA_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:6009
GenAtlas
IL2RB
GeneCards
IL2RB
GenBank Gene Database
M26062
GenBank Protein Database
307048
Guide to Pharmacology
1696
UniProt Accession
IL2RB_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:3620
GenAtlas
FCGR3B
GeneCards
FCGR3B
GenBank Gene Database
X16863
GenBank Protein Database
31322
UniProt Accession
FCG3B_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:1246
GenAtlas
C1R
GeneCards
C1R
GenBank Gene Database
X04701
GenBank Protein Database
29539
Guide to Pharmacology
2334
UniProt Accession
C1R_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:1241
GenAtlas
C1QA
GeneCards
C1QA
GenBank Gene Database
AF135157
GenBank Protein Database
4894854
UniProt Accession
C1QA_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:1242
GenAtlas
C1QB
GeneCards
C1QB
GenBank Gene Database
X03084
GenBank Protein Database
573114
UniProt Accession
C1QB_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:1245
GenAtlas
C1QC
GeneCards
C1QC
GenBank Gene Database
AF087892
GenBank Protein Database
33150626
UniProt Accession
C1QC_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:3619
GenAtlas
FCGR3A
GeneCards
FCGR3A
GenBank Gene Database
X52645
GenBank Protein Database
31324
Guide to Pharmacology
3017
UniProt Accession
FCG3A_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:3613
GenAtlas
FCGR1A
GeneCards
FCGR1A
GenBank Gene Database
X14356
GenBank Protein Database
31332
UniProt Accession
FCGR1_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:3616
GenAtlas
FCGR2A
GeneCards
FCGR2A
GenBank Gene Database
M31932
GenBank Protein Database
182474
UniProt Accession
FCG2A_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:3618
GenAtlas
FCGR2B
GeneCards
FCGR2B
GenBank Gene Database
U87560
GenBank Protein Database
4099445
UniProt Accession
FCG2B_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:15626
GenAtlas
FCGR2C
GeneCards
FCGR2C
GenBank Gene Database
X17652
GenBank Protein Database
32074
UniProt Accession
FCG2C_HUMAN
DrugBank citations
If you use DrugBank data in your research, please cite the following publications: